Variables | Major adverse cardiovascular events | ||
---|---|---|---|
HR | 95% CI | P value | |
Mean heart rate (ref: < 60 bpm) | |||
 60–69 bpm | 1.13 | (1.01–1.26) | .03 |
 70–79 bpm | 1.35 | (1.22–1.50) | < .001 |
 80–89 bpm | 1.64 | (1.47–1.83) | < .001 |
 ≥ 90 bpm | 2.08 | (1.85–2.34) | < .001 |
Age | 1.02 | (1.02–1.03) | < .001 |
Male (ref: female) | 1.20 | (1.14–1.27) | < .001 |
Stroke severity (ref: mild, eNIHSS ≤ 5) | |||
 Moderate, eNIHSS 6–13 | 1.23 | (1.16–1.31) | < .001 |
 Severe, eNIHSS > 13 | 2.47 | (2.31–2.63) | < .001 |
Medical history | |||
 Hypertension (ref: without hypertension) | 0.92 | (0.87–0.98) | .005 |
 DM (ref: without DM) | 1.10 | (1.04–1.16) | < .001 |
 Dyslipidemia (ref: without dyslipidemia) | 0.89 | (0.85–0.94) | < .001 |
 AF (ref: without AF) | 1.00 | (0.94–1.07) | .98 |
 CAD (ref: without CAD) | 1.10 | (1.02–1.18) | .01 |
 HF (ref: without HF) | 1.27 | (1.17–1.39) | < .001 |
 History of cancer (ref: without Cancer) | 1.60 | (1.48–1.73) | < .001 |
Current smoker (ref: non-smoker) | 1.08 | (1.02–1.14) | .009 |
Body mass index (ref: ≥ 18.5, < 24) | |||
 < 18.5 | 0.79 | (0.70–0.88) | < .001 |
 ≥ 24, < 27 | 0.70 | (0.62–0.79) | < .001 |
 ≥ 27, < 30 | 0.73 | (0.64–0.83) | < .001 |
 ≥ 30 | 0.69 | (0.59–0.80) | < .001 |
Laboratory data | |||
 Total cholesterol (ref: ≤ Q1) | |||
  > Q1, ≤ median | 0.94 | (0.87–1.02) | .11 |
  > median, ≤ Q3 | 0.94 | (0.85–1.04) | .21 |
  > Q3 | 0.92 | (0.81–1.04) | .19 |
 Triglyceride (ref: ≤ Q1) | |||
  > Q1, ≤ median | 0.92 | (0.87–0.98) | .01 |
  > median, ≤ Q3 | 0.94 | (0.88–1.00) | .06 |
  > Q3 | 0.98 | (0.91–1.06) | .63 |
 LDL cholesterol (ref: ≤ Q1) | |||
  > Q1, ≤ median | 0.99 | (0.91–1.06) | .70 |
  > median, ≤ Q3 | 0.98 | (0.88–1.07) | .60 |
  > Q3 | 0.99 | (0.88–1.12) | .87 |
 CKD (ref: stage 1) | |||
  Stage 2 | 1.08 | (1.02–1.15) | .01 |
  Stage 3–5 | 1.42 | (1.34–1.51) | < .001 |
 Alanine aminotransferase (ref: ≤ Q1) | |||
  > Q1, ≤ median | 0.88 | (0.83–0.94) | < .001 |
  > median, ≤ Q3 | 0.86 | (0.81–0.92) | < .001 |
  > Q3 | 0.93 | (0.87–0.99) | .02 |
 HbA1c (ref: ≤ Q1) |  |  |  |
  > Q1, ≤ median | 1.00 | (0.92–1.09) | .95 |
  > median, ≤ Q3 | 1.03 | (0.95–1.13) | .47 |
  > Q3 | 1.10 | (1.00–1.21) | .06 |
Mean SBP (ref: < 130 mmHg) | |||
 ≥ 130, < 140 mmHg | 0.94 | (0.87–1.02) | .16 |
 ≥ 140, < 150 mmHg | 0.98 | (0.90–1.07) | .66 |
 ≥ 150, < 160 mmHg | 1.03 | (0.94–1.12) | .60 |
 ≥ 160 mmHg | 1.12 | (1.02–1.23) | .02 |
Mean DBP (ref: < 70 mmHg) | |||
 ≥ 70, < 80 mmHg | 0.85 | (0.78–0.92) | < .001 |
 ≥ 80, < 90 mmHg | 0.72 | (0.66–0.79) | < .001 |
 ≥ 90, < 100 mmHg | 0.75 | (0.67–0.83) | < .001 |
 ≥ 100 mmHg | 0.70 | (0.61–0.80) | < .001 |
Medication at discharge | |||
 Antithrombotics | 0.57 | (0.52–0.62) | < .001 |
 Statins | 0.94 | (0.88–0.99) | .02 |
 Beta-blockers | 0.99 | (0.94–1.04) | .68 |